지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한핵의학회 Nuclear medicine and molecular imaging : NMMI Nuclear medicine and molecular imaging : NMMI 제46권 제4호
- 발행연도
- 2012.1
- 수록면
- 261 - 268 (8page)
이용수
초록· 키워드
오류제보하기
Purpose Usefulness of FDG PET-CT in monitoring response in locally advanced gastric cancer has been reported. The purpose of this study was to evaluate the related factors to detect measurable diseases in advanced gastric cancer on FDG PET-CT. Methods We retrospectively reviewed 38 patients diagnosed as having advanced gastric cancer. We defined the measurable diseases when there was visualized tumor of which maximum standardized uptake value (SUVmax) was higher than $1.35^*SUVmax$ of liver + $2^*SD$ of liver SUV. We evaluated what kinds of factors from the clinicopathologic features were related to identifying measurable diseases. Results Of 38 patients with advanced gastric cancer, 18 (50 %) had measurable tumors on FDG PET-CT. Measurable tumors were significantly more frequent in well or moderately differentiated adenocarcinoma (70.5 % vs 35.3 %, p<0.05), in the tumors located at antrum or angle (66.7 % vs 29.4 %, p<0.05) and in the elderly group (age of 55 years old or more, 72.0 % vs 8.3 %, p<0.001) than the others, respectively. By multivariate analysis, age at diagnosis was the only independent predictor for the measurable disease on FDG PET-CT. Conclusion We found that age at diagnosis, as well as histologic types and location of tumors, were the affecting factors to detect measurable disease on FDG PET-CT in patients with advanced gastric cancer. Our study suggests that elderly patients of age of 55 years old or more can frequently have T-measurable disease on FDG PET-CT in advanced gastric cancer and FDG PET-CT will be helpful to monitor measurable disease.
목차
등록된 정보가 없습니다.
참고문헌 (19)
참고문헌 신청
Couper GW / 1998 / The detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer / Brit J Surg 85:31
Lordick F / 2007 / PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial / Lancet Oncol 8(9):797~805
Ott K / 2003 / Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial / J Clin Oncol Off J Am Soc Clin Oncol 21(24):4604~4610
Ott K / 2008 / Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study / Clin Cancer Res Off J Am Assoc Cancer Res 14(7):2012~2018
Ott K / 2006 / Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction / Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 24(29):4692~4698
Lordick F / 2007 / PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial / Lancet Oncol 8(9):797~805
Ott K / 2003 / Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial / J Clin Oncol Off J Am Soc Clin Oncol 21(24):4604~4610
Ott K / 2008 / Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study / Clin Cancer Res Off J Am Assoc Cancer Res 14(7):2012~2018
Ott K / 2006 / Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction / Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 24(29):4692~4698
이 논문의 저자 정보
최근 본 자료
댓글(0)
0